Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Una sperimentazione di fase 3 per valutare CYB003 nel disturbo depressivo maggiore (EMBRACE)

12 novembre 2026 aggiornato da: Cybin IRL Limited

Un'efficacia e una sicurezza, fase III, studio multicentrico, in doppio cieco, randomizzato controllato che confronta 2 dosi attive di cyb003 e placebo nei partecipanti ammissibili con disturbo depressivo maggiore

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

330

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Reclutamento
        • Royal Prince Alfred Hospital
        • Investigatore principale:
          • Nicholas Glozier
    • Queensland
      • Maroochydore, Queensland, Australia, 4558
        • Reclutamento
        • Thompson Brain & Mind Healthcare (TBMH)
        • Investigatore principale:
          • Adem Can
        • Contatto:
        • Contatto:
    • Victoria
      • Melbourne, Victoria, Australia, 3004
      • Melbourne, Victoria, Australia, 3053
        • Reclutamento
        • Neurocentrix Research
        • Investigatore principale:
          • David Barton
        • Contatto:
        • Contatto:
      • Notting Hill, Victoria, Australia, 3168
        • Reclutamento
        • Monash University - Notting Hill
        • Contatto:
        • Investigatore principale:
          • Paul Liknaitzky
      • Prague, Cechia
        • Non ancora reclutamento
        • Institute of neuropsychiatric Care (INEP)
        • Investigatore principale:
          • Alexander Nawka
        • Contatto:
      • Prague, Cechia
        • Non ancora reclutamento
        • Psyon s.r.o.
        • Investigatore principale:
          • Tomas Palenicek
        • Contatto:
      • Předměstí, Cechia
        • Non ancora reclutamento
        • A-SHINE s.r.o.
        • Investigatore principale:
          • Lubos Janu
        • Contatto:
      • Berlin, Germania, 10117
        • Non ancora reclutamento
        • Charité Universitaetsmedizin Berlin
        • Investigatore principale:
          • Michael Koslowski
        • Contatto:
      • Frankfurt am Main, Germania, 60528
        • Non ancora reclutamento
        • University Hospital Frankfurt
        • Investigatore principale:
          • Andreas Reif
        • Contatto:
      • Mannheim, Germania, 68159
        • Non ancora reclutamento
        • Central Institute of Mental Health
        • Contatto:
        • Investigatore principale:
          • Gerhard Grüender
    • Saarland
      • Homburg, Saarland, Germania, 66421
        • Non ancora reclutamento
        • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
        • Investigatore principale:
          • Matthias Riemenschneider
        • Contatto:
        • Contatto:
      • Athens, Grecia, 12462
        • Reclutamento
        • Attikon University Hospital
        • Investigatore principale:
          • Nikolaos Smyrnis
        • Contatto:
      • Athens, Grecia, 11528
        • Reclutamento
        • Eginitio Hospital
        • Investigatore principale:
          • Nikos Stefanis
        • Contatto:
      • Thessaloniki, Grecia, 56404
        • Reclutamento
        • Papageorgiou General Hospital
        • Investigatore principale:
          • Georgios Papazisis
        • Contatto:
      • Dublin, Irlanda, D24 WK80
        • Reclutamento
        • Sheaf House - Tallaght Adult Mental Health Service
        • Investigatore principale:
          • John Kelly
        • Contatto:
      • Galway, Irlanda, H91 VE03
        • Reclutamento
        • La Nua Day Hospital Mental Health Centre
        • Contatto:
        • Investigatore principale:
          • Shane McInerney
      • Bialystok, Polonia, 15-272
        • Ritirato
        • Uniwersytecki Szpital Kliniczny W Białymstoku
      • Bydgoszcz, Polonia, 85-133
        • Reclutamento
        • Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
        • Contatto:
        • Investigatore principale:
          • Katarzyna Lachut
      • Gdansk, Polonia, 80-546
        • Reclutamento
        • Centrum Badan Klinicznych PI-House Sp. z o.o
        • Contatto:
        • Investigatore principale:
          • Hanna Badzio-Jagiello
      • Gdansk, Polonia, 80-214
        • Non ancora reclutamento
        • UCK
        • Investigatore principale:
          • Wieslaw Jerzy Cubala
        • Contatto:
      • Warsaw, Polonia, 02-957
        • Non ancora reclutamento
        • Department of Pharmacology and Physiology of CNS
        • Investigatore principale:
          • Justyna Holka-Pokorska
      • Warsaw, Polonia, 02-172
        • Reclutamento
        • MTZ Clinical Research Powered by Pratia
        • Investigatore principale:
          • Monika Gawlowicz
      • Cambridge, Regno Unito, CB1 2EU
        • Reclutamento
        • Cambridge University Hospital NHS
        • Investigatore principale:
          • Liliana Galindo
        • Contatto:
        • Contatto:
      • Doncaster, Regno Unito, DN4 8QN
        • Reclutamento
        • Clerkenwell Health - Doncaster
        • Investigatore principale:
          • Paul Morrison
        • Contatto:
      • Edinburgh, Regno Unito, EH16 4TJ
        • Non ancora reclutamento
        • NHS Research Scotland
        • Investigatore principale:
          • Donald MacIntyre
        • Contatto:
      • Glasgow, Regno Unito, G51 4TF
        • Non ancora reclutamento
        • Queen Elizabeth University Hospital
        • Investigatore principale:
          • Maytal Wolfe
        • Contatto:
      • Liverpool, Regno Unito, L7 8XP
        • Non ancora reclutamento
        • Royal Liverpool Hospital
        • Contatto:
        • Investigatore principale:
          • Fabian Devlin
      • London, Regno Unito, EC2Y 8EA
        • Reclutamento
        • St Pancras Clinical Research
        • Investigatore principale:
          • Martin Johnson
        • Contatto:
      • London, Regno Unito, W1U 6RP
      • London, Regno Unito, W1G9 RU
        • Reclutamento
        • Re:Cognition Health
        • Investigatore principale:
          • Dimitrios Paschos
        • Contatto:
          • Numero di telefono: +44-0800-802-1030
      • London, Regno Unito, SE5 9RS
      • London, Regno Unito, W1G 8DR
        • Ritirato
        • Clerkenwell Health - Welbeck Street
      • Newcastle upon Tyne, Regno Unito, NE4 5PL
      • Reading, Regno Unito, RG7 8PA
        • Reclutamento
        • Ascend Clinical Research
        • Investigatore principale:
          • Pamela Walters
        • Contatto:
      • Sheffield, Regno Unito, S4 7QQ
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35209
        • Reclutamento
        • UAB Psychiatry and Behavioral Neurology
        • Contatto:
        • Investigatore principale:
          • Peter Hendricks
        • Contatto:
    • Arizona
      • Gilbert, Arizona, Stati Uniti, 85234
        • Reclutamento
        • Lighthouse Psychiatry
        • Contatto:
        • Investigatore principale:
          • Frank Genova
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72204
        • Ritirato
        • Pillar Clinical Research - Little Rock
    • California
      • Glendale, California, Stati Uniti, 91206
        • Reclutamento
        • Behavioral Research Specialists, LLC
        • Investigatore principale:
          • Jesse Carr
        • Contatto:
      • Imperial, California, Stati Uniti, 92251
        • Ritirato
        • Sun Valley Research Center
      • Los Angeles, California, Stati Uniti, 90025
        • Reclutamento
        • CalNeuro Research Group
        • Investigatore principale:
          • Alexander Bystritsky
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90025
        • Reclutamento
        • Lipov Medical Group
        • Contatto:
        • Investigatore principale:
          • Jacob Moussai
      • Orange, California, Stati Uniti, 92868
        • Reclutamento
        • NRC Research Institute
        • Contatto:
        • Investigatore principale:
          • Daniel Chueh
      • Orange, California, Stati Uniti, 92866
        • Reclutamento
        • ATP Clinical Research
        • Investigatore principale:
          • Gustavo Alva
        • Contatto:
      • San Juan Capistrano, California, Stati Uniti, 92675
        • Reclutamento
        • Inland Psychiatric Medical Group Inc (IPMG Research)
        • Investigatore principale:
          • Neelima Kunam
        • Contatto:
      • Santa Monica, California, Stati Uniti, 90404
        • Reclutamento
        • Psychedelic Science Institute
        • Investigatore principale:
          • Keith Heinzerling
        • Contatto:
      • Stanford, California, Stati Uniti, 94305
        • Ritirato
        • Stanford University
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06511
        • Reclutamento
        • Yale School of Medicine - Yale Program for Psychedelic Science
        • Investigatore principale:
          • Ben Kelmendi
        • Contatto:
          • Daidre Chamberlain
          • Numero di telefono: 203-693-1591
          • Email: enact@yale.edu
        • Contatto:
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32256
        • Reclutamento
        • CNS Healthcare
        • Contatto:
          • Numero di telefono: 904-281-5757
        • Investigatore principale:
          • John Mark Joyce
      • Maitland, Florida, Stati Uniti, 32751
        • Reclutamento
        • Accel Research Sites - Maitland
        • Contatto:
          • Numero di telefono: 407-644-1165
        • Investigatore principale:
          • Andrea Marrafino
      • Naples, Florida, Stati Uniti, 34105
        • Reclutamento
        • Aqualane Clinical Research
        • Investigatore principale:
          • Matthew Baker
        • Contatto:
      • Tampa, Florida, Stati Uniti, 33634
        • Reclutamento
        • K2 Medical Research Tampa
        • Investigatore principale:
          • Kelley Wilson
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30329
        • Ritirato
        • Emory University Dept of Psychiatry and Behavioral Studies
      • Marietta, Georgia, Stati Uniti, 30060
        • Reclutamento
        • Psych Atlanta
        • Investigatore principale:
          • Michael Banov
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Reclutamento
        • Rush University
        • Investigatore principale:
          • Joshua Eloge
        • Contatto:
    • Louisiana
      • Marrero, Louisiana, Stati Uniti, 70006
        • Ritirato
        • Tandem Clinical Research
      • New Orleans, Louisiana, Stati Uniti, 70115
        • Reclutamento
        • Atlas Psychiatry
        • Contatto:
        • Investigatore principale:
          • Nicholas Pejic
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21224
        • Ritirato
        • Johns Hopkins Medicine
      • Rockville, Maryland, Stati Uniti, 20850
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02116
        • Reclutamento
        • Adams Clinical Boston
        • Investigatore principale:
          • Darin Dougherty
        • Contatto:
      • Watertown, Massachusetts, Stati Uniti, 02472
        • Reclutamento
        • Adams Clinical Watertown
        • Investigatore principale:
          • Stephanie Ellickson
        • Contatto:
    • Minnesota
      • Eden Prairie, Minnesota, Stati Uniti, 55347
        • Reclutamento
        • Institute for Integrative Therapies
        • Investigatore principale:
          • Manoj Doss
        • Contatto:
      • Golden Valley, Minnesota, Stati Uniti, 55427
        • Non ancora reclutamento
        • The Remedy Mental Health
        • Contatto:
        • Investigatore principale:
          • Wayne Bentham
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89119
        • Reclutamento
        • Redbird Research, LLC
        • Investigatore principale:
          • Jelena Kunovac
        • Contatto:
    • New Jersey
      • Toms River, New Jersey, Stati Uniti, 08755
        • Reclutamento
        • Bio Behavioral Health
        • Contatto:
        • Investigatore principale:
          • Ashok Patel
    • New York
      • New York, New York, Stati Uniti, 10032
        • Non ancora reclutamento
        • New York State Psychiatric Institute
        • Investigatore principale:
          • Natalie Gukasyan
        • Contatto:
      • New York, New York, Stati Uniti, 10029
        • Reclutamento
        • Adams Clinical Harlem
        • Contatto:
        • Investigatore principale:
          • Wesley Gregory
      • The Bronx, New York, Stati Uniti, 10461
        • Reclutamento
        • Adams Clinical Bronx
        • Investigatore principale:
          • Shama Farooq
        • Contatto:
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73112
        • Ritirato
        • SP Research PLLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Adams Clinical Philadelphia
        • Investigatore principale:
          • Cassie Blanchard
        • Contatto:
      • Philadelphia, Pennsylvania, Stati Uniti, 19462
        • Reclutamento
        • Flourish Research Philadelphia
        • Investigatore principale:
          • Rachna Saralkar
        • Contatto:
          • Numero di telefono: 215-614-5606
    • Texas
      • Austin, Texas, Stati Uniti, 78737
        • Ritirato
        • Austin Clinical Trial Partners
      • DeSoto, Texas, Stati Uniti, 75115
        • Reclutamento
        • Adams Clinical Dallas
        • Investigatore principale:
          • Rajinder Shiwach
        • Contatto:
      • Fort Worth, Texas, Stati Uniti, 76104
        • Ritirato
        • North Texas Clinical Trials
      • Houston, Texas, Stati Uniti, 77046
        • Reclutamento
        • Brain Health Consultants and TMS Center
        • Investigatore principale:
          • Lauren Marangell
        • Contatto:
      • San Antonio, Texas, Stati Uniti, 78229
    • Washington
      • Everett, Washington, Stati Uniti, 98201
        • Non ancora reclutamento
        • Core Clinical Research
        • Contatto:
        • Investigatore principale:
          • James Knutson
      • Seattle, Washington, Stati Uniti, 98104
        • Reclutamento
        • Seattle Neuropsychiatric Treatment Center
        • Investigatore principale:
          • Rebecca Allen
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 85 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Age18 to 85 years.
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Moderate to severe depression at Screening and Baseline, independently confirmed.
  • Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
  • Participants have a presence or relevant history of organic brain disorders.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
  • Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Sperimentale: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Comparatore placebo: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Manualized psychological support performed by facilitator.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Montgomery-Asberg Depression Scale (MADRS)
Lasso di tempo: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity.

The total score ranges 0-60, higher scores denote greater severity.

Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The Beck Depression Inventory - Second Edition (BDI-II)
Lasso di tempo: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.

Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0.

Day -1, Day 21, Day 42 and Day 84/End of Trial.
The Clinical Global Impression Scale (CGI-S)
Lasso di tempo: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.

The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index.

Only the severity of illness ang global improvement measures will be utilized for this trial.

Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:

  1. = Normal, not at all ill
  2. = Borderline ill
  3. = Mildly ill
  4. = Moderately ill
  5. = Markedly ill
  6. = Severely ill
  7. = Among the most extremely ill patients
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Lasso di tempo: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms.

Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows:

Scores represent:

0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety

Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Lasso di tempo: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities.

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.

Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70

Day -1, Day 21, Day 42 and Day 84/End of Trial.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Direttore dello studio: Felix Mazer, Cybin IRL Limited

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 dicembre 2025

Completamento primario (Stimato)

7 giugno 2027

Completamento dello studio (Stimato)

9 agosto 2027

Date di iscrizione allo studio

Primo inviato

21 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

21 gennaio 2025

Primo Inserito (Effettivo)

27 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CYB003-003

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .